Johnson & Johnson (NYSE:JNJ), a US-based pharmaceutical and biotechnology company, reported on Saturday that new analyses from the Phase 3 MARIPOSA study shows that first-line treatment with RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) significantly reduces the development of epidermal growth factor receptor (EGFR)- and MET-driven resistance compared with osimertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC) with exon 19 deletion (ex19del) or L858R mutations (Poster Abstract PT1.03).

According to Johnson & Johnson, resistance data builds on the combination's previously reported and unmatched overall survival benefit in a chemotherapy-free regimen, which is projected to exceed four years, one year beyond the median observed with osimertinib, and underscore its potential to change the biology of the disease by preventing acquired resistance. Late-breaking results are being presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Congress on Lung Cancer (WCLC).

Consistent with prior data presented at the European Society for Medical Oncology (ESMO) 2024 Congress, the company says that these updated analyses from the MARIPOSA study confirm that patients treated with RYBREVANT plus LAZCLUZE were less likely to develop the two main types of resistance (MET amplification and EGFR mutations) compared to those treated with osimertinib alone.

The safety profile of RYBREVANT plus LAZCLUZE was reportedly consistent with the primary analysis and no new safety signals emerged with longer-term follow-up.

RYBREVANT plus LAZCLUZE is approved in the United States, Europe and other markets around the world for patients with first-line EGFR-mutated NSCLC based on the Phase 3 MARIPOSA study.